Using marginal structural models to analyze randomized clinical trials with non-adherence and lost to follow up

•Unlike the Intention-to-Treat approach, Marginal Structural Models can account for the effects of time-varying treatments in the presence of censoring and time-dependent confounding influenced by prior treatment.•A randomized clinical trial on asthma treatment was used as working model to determine...

Full description

Saved in:
Bibliographic Details
Published inAnnals of epidemiology Vol. 63; pp. 22 - 28
Main Authors Lancet, Elizabeth A., Borrell, Luisa N., Holbrook, Janet, Morabia, Alfredo
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.11.2021
Subjects
Online AccessGet full text

Cover

Loading…
Abstract •Unlike the Intention-to-Treat approach, Marginal Structural Models can account for the effects of time-varying treatments in the presence of censoring and time-dependent confounding influenced by prior treatment.•A randomized clinical trial on asthma treatment was used as working model to determine whether the use of Marginal Structural Models to adjust for post-randomization bias would change the results of the original Intention-to-Treat analysis.•Despite the occurrence of non-adherence and censorship, the use of Marginal Structural Models did not change the findings of the original Intention-to-Treat analysis. Our findings are comparable to that of other trials with similar proportions of non-adherence and censorship comparing Marginal Structural Models to Intention-to-Treat.•Because no adherence or censorship thresholds currently exist to assist researchers to determine when Marginal Structural Models may be superior to Intention-to-Treat, Marginal Structural Models are recommended as a sensitivity analysis to the Intention-to-Treat approach in clinical trials with non-adherence and censorship. In the presence of non-adherence and lost to follow up, results of an Intention to Treat (ITT) analysis may be biased as it is measuring the effect of assignment rather than the effect of treatment. Given that Marginal Structural Models (MSMs) adjust for such issues, this study examines the use of MSMs to assess the validity of ITT analyses in the presence of non-adherence and lost to follow up in an existing randomized clinical trial on asthma treatment. Inverse probability weights were obtained from a pooled logistic regression assessing the probability of staying on assigned treatment (adherence) and of remaining uncensored (censored) for subjects at each visit by treatment arm. Weights were then pooled into a MSM analysis using a Poisson generalized estimating equation with an independent correlation matrix. Out of 488 participants, 174 (36%) did not adhere to the baseline assignment and 85 (17%) were lost to follow up by the end of the study. The adjusted relative risks (RR), and 95% confidence intervals (CI), obtained from the MSMs (theophylline vs. montelukast; RR=1.24; 95% CI: 0.83,1.84; theophylline vs. placebo: RR=1.01; 95% CI: 0.70,1.48; and montelukast vs. placebo: RR=0.83; 95% CI: 0.57,1.19) were nearly identical to that of the ITT analysis (theophylline vs. montelukast: RR=1.22; 95% CI: 0.82,1.86; theophylline vs. placebo: RR=0.99; 95% CI: 0.67,1.50; and montelukast vs. placebo: RR=0.82; 95% CI: 0.55,1.21). Concordance between the results of ITT and MSMs indicate adherence and censoring may not invalidate ITT analysis. However, no adherence or censorship thresholds currently exist to assist researchers in determining when MSMs may be superior to ITT in the analysis of clinical trials with non-adherence or censorship issues, and therefore, MSMs should be conducted as a sensitivity analysis to the ITT approach in clinical trials.
AbstractList •Unlike the Intention-to-Treat approach, Marginal Structural Models can account for the effects of time-varying treatments in the presence of censoring and time-dependent confounding influenced by prior treatment.•A randomized clinical trial on asthma treatment was used as working model to determine whether the use of Marginal Structural Models to adjust for post-randomization bias would change the results of the original Intention-to-Treat analysis.•Despite the occurrence of non-adherence and censorship, the use of Marginal Structural Models did not change the findings of the original Intention-to-Treat analysis. Our findings are comparable to that of other trials with similar proportions of non-adherence and censorship comparing Marginal Structural Models to Intention-to-Treat.•Because no adherence or censorship thresholds currently exist to assist researchers to determine when Marginal Structural Models may be superior to Intention-to-Treat, Marginal Structural Models are recommended as a sensitivity analysis to the Intention-to-Treat approach in clinical trials with non-adherence and censorship. In the presence of non-adherence and lost to follow up, results of an Intention to Treat (ITT) analysis may be biased as it is measuring the effect of assignment rather than the effect of treatment. Given that Marginal Structural Models (MSMs) adjust for such issues, this study examines the use of MSMs to assess the validity of ITT analyses in the presence of non-adherence and lost to follow up in an existing randomized clinical trial on asthma treatment. Inverse probability weights were obtained from a pooled logistic regression assessing the probability of staying on assigned treatment (adherence) and of remaining uncensored (censored) for subjects at each visit by treatment arm. Weights were then pooled into a MSM analysis using a Poisson generalized estimating equation with an independent correlation matrix. Out of 488 participants, 174 (36%) did not adhere to the baseline assignment and 85 (17%) were lost to follow up by the end of the study. The adjusted relative risks (RR), and 95% confidence intervals (CI), obtained from the MSMs (theophylline vs. montelukast; RR=1.24; 95% CI: 0.83,1.84; theophylline vs. placebo: RR=1.01; 95% CI: 0.70,1.48; and montelukast vs. placebo: RR=0.83; 95% CI: 0.57,1.19) were nearly identical to that of the ITT analysis (theophylline vs. montelukast: RR=1.22; 95% CI: 0.82,1.86; theophylline vs. placebo: RR=0.99; 95% CI: 0.67,1.50; and montelukast vs. placebo: RR=0.82; 95% CI: 0.55,1.21). Concordance between the results of ITT and MSMs indicate adherence and censoring may not invalidate ITT analysis. However, no adherence or censorship thresholds currently exist to assist researchers in determining when MSMs may be superior to ITT in the analysis of clinical trials with non-adherence or censorship issues, and therefore, MSMs should be conducted as a sensitivity analysis to the ITT approach in clinical trials.
In the presence of non-adherence and lost to follow up, results of an Intention to Treat (ITT) analysis may be biased as it is measuring the effect of assignment rather than the effect of treatment. Given that Marginal Structural Models (MSMs) adjust for such issues, this study examines the use of MSMs to assess the validity of ITT analyses in the presence of non-adherence and lost to follow up in an existing randomized clinical trial on asthma treatment. Inverse probability weights were obtained from a pooled logistic regression assessing the probability of staying on assigned treatment (adherence) and of remaining uncensored (censored) for subjects at each visit by treatment arm. Weights were then pooled into a MSM analysis using a Poisson generalized estimating equation with an independent correlation matrix. Out of 488 participants, 174 (36%) did not adhere to the baseline assignment and 85 (17%) were lost to follow up by the end of the study. The adjusted relative risks (RR), and 95% confidence intervals (CI), obtained from the MSMs (theophylline vs. montelukast; RR=1.24; 95% CI: 0.83,1.84; theophylline vs. placebo: RR=1.01; 95% CI: 0.70,1.48; and montelukast vs. placebo: RR=0.83; 95% CI: 0.57,1.19) were nearly identical to that of the ITT analysis (theophylline vs. montelukast: RR=1.22; 95% CI: 0.82,1.86; theophylline vs. placebo: RR=0.99; 95% CI: 0.67,1.50; and montelukast vs. placebo: RR=0.82; 95% CI: 0.55,1.21). Concordance between the results of ITT and MSMs indicate adherence and censoring may not invalidate ITT analysis. However, no adherence or censorship thresholds currently exist to assist researchers in determining when MSMs may be superior to ITT in the analysis of clinical trials with non-adherence or censorship issues, and therefore, MSMs should be conducted as a sensitivity analysis to the ITT approach in clinical trials.
In the presence of non-adherence and lost to follow up, results of an Intention to Treat (ITT) analysis may be biased as it is measuring the effect of assignment rather than the effect of treatment. Given that Marginal Structural Models (MSMs) adjust for such issues, this study examines the use of MSMs to assess the validity of ITT analyses in the presence of non-adherence and lost to follow up in an existing randomized clinical trial on asthma treatment.BACKGROUNDIn the presence of non-adherence and lost to follow up, results of an Intention to Treat (ITT) analysis may be biased as it is measuring the effect of assignment rather than the effect of treatment. Given that Marginal Structural Models (MSMs) adjust for such issues, this study examines the use of MSMs to assess the validity of ITT analyses in the presence of non-adherence and lost to follow up in an existing randomized clinical trial on asthma treatment.Inverse probability weights were obtained from a pooled logistic regression assessing the probability of staying on assigned treatment (adherence) and of remaining uncensored (censored) for subjects at each visit by treatment arm. Weights were then pooled into a MSM analysis using a Poisson generalized estimating equation with an independent correlation matrix.METHODSInverse probability weights were obtained from a pooled logistic regression assessing the probability of staying on assigned treatment (adherence) and of remaining uncensored (censored) for subjects at each visit by treatment arm. Weights were then pooled into a MSM analysis using a Poisson generalized estimating equation with an independent correlation matrix.Out of 488 participants, 174 (36%) did not adhere to the baseline assignment and 85 (17%) were lost to follow up by the end of the study. The adjusted relative risks (RR), and 95% confidence intervals (CI), obtained from the MSMs (theophylline vs. montelukast; RR=1.24; 95% CI: 0.83,1.84; theophylline vs. placebo: RR=1.01; 95% CI: 0.70,1.48; and montelukast vs. placebo: RR=0.83; 95% CI: 0.57,1.19) were nearly identical to that of the ITT analysis (theophylline vs. montelukast: RR=1.22; 95% CI: 0.82,1.86; theophylline vs. placebo: RR=0.99; 95% CI: 0.67,1.50; and montelukast vs. placebo: RR=0.82; 95% CI: 0.55,1.21).RESULTSOut of 488 participants, 174 (36%) did not adhere to the baseline assignment and 85 (17%) were lost to follow up by the end of the study. The adjusted relative risks (RR), and 95% confidence intervals (CI), obtained from the MSMs (theophylline vs. montelukast; RR=1.24; 95% CI: 0.83,1.84; theophylline vs. placebo: RR=1.01; 95% CI: 0.70,1.48; and montelukast vs. placebo: RR=0.83; 95% CI: 0.57,1.19) were nearly identical to that of the ITT analysis (theophylline vs. montelukast: RR=1.22; 95% CI: 0.82,1.86; theophylline vs. placebo: RR=0.99; 95% CI: 0.67,1.50; and montelukast vs. placebo: RR=0.82; 95% CI: 0.55,1.21).Concordance between the results of ITT and MSMs indicate adherence and censoring may not invalidate ITT analysis. However, no adherence or censorship thresholds currently exist to assist researchers in determining when MSMs may be superior to ITT in the analysis of clinical trials with non-adherence or censorship issues, and therefore, MSMs should be conducted as a sensitivity analysis to the ITT approach in clinical trials.CONCLUSIONConcordance between the results of ITT and MSMs indicate adherence and censoring may not invalidate ITT analysis. However, no adherence or censorship thresholds currently exist to assist researchers in determining when MSMs may be superior to ITT in the analysis of clinical trials with non-adherence or censorship issues, and therefore, MSMs should be conducted as a sensitivity analysis to the ITT approach in clinical trials.
Author Holbrook, Janet
Lancet, Elizabeth A.
Morabia, Alfredo
Borrell, Luisa N.
Author_xml – sequence: 1
  givenname: Elizabeth A.
  surname: Lancet
  fullname: Lancet, Elizabeth A.
  email: Elizabeth.Lancet13@sphmail.cuny.edu
  organization: Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York, New York, NY
– sequence: 2
  givenname: Luisa N.
  surname: Borrell
  fullname: Borrell, Luisa N.
  organization: Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York, New York, NY
– sequence: 3
  givenname: Janet
  surname: Holbrook
  fullname: Holbrook, Janet
  organization: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
– sequence: 4
  givenname: Alfredo
  surname: Morabia
  fullname: Morabia, Alfredo
  organization: Barry Commoner Center for Health and the Environment, Queens College, City University of New York, Flushing, NY
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34289408$$D View this record in MEDLINE/PubMed
BookMark eNqNkUtv1DAUhS1URB_wFyBLNgl-JXYWCFUVL6kSG7q2HPum9eDYg-1QTX89Hk2HRTd05Svf75xr33OOTkIMgNA7gjuCyfBh0-kQYOssLB3FlHRYdBiTF-iMSMFa2sv-pNaYi5aKUZyi85w3GGMhBX2FThmncuRYnqF4k124bRadbl3QvsklraasqZZLtOBzU2Kja2f3AE3SwcbFPYBtjHfBmUqV5HSl7l25a-ojW23vIEEwUFW28TGXvcMcvY_3zbp9jV7OlYc3j-cFuvny-efVt_b6x9fvV5fXreFUlJaN2lg-UcnthGc5wyTwjIFRQcexXgtGBsnpaGkPowTOzDANtanrD7nWA7tA7w--2xR_r5CLWlw24L0OENesaN9z1nNKWEXfPqLrtIBV2-TqOnbquKQKfDwAJsWcE8zKuKKLi6Ek7bwiWO1DURv1LxS1D0VhoWooVS-e6I8j_q-8PChrEPDHQVLZuP1yrUtgirLRPcPj0xOPY3a_YPcsh79H5MKu
CitedBy_id crossref_primary_10_1097_QAD_0000000000004105
Cites_doi 10.1097/MLR.0b013e31806518ac
10.1002/sim.3801
10.1016/j.conctc.2016.10.005
10.1007/s13665-012-0024-y
10.1016/j.jaci.2011.12.986
10.1164/rccm.200603-416OC
10.1001/jama.288.3.321
10.1002/sim.3585
10.1177/2167696815621645
10.2202/1557-4679.1117
10.1177/1740774511420743
10.1093/aje/kwn164
10.1093/aje/kwh131
10.1037/a0022610
10.1002/sim.1144
10.1097/EDE.0b013e3181df1b69
10.1046/j.1365-2125.2002.01628.x
10.1093/biostatistics/kxq054
10.1097/00001648-200009000-00011
10.1093/aje/155.11.1045
ContentType Journal Article
Copyright 2021 Elsevier Inc.
Copyright © 2021 Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2021 Elsevier Inc.
– notice: Copyright © 2021 Elsevier Inc. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.annepidem.2021.07.001
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
EISSN 1873-2585
EndPage 28
ExternalDocumentID 34289408
10_1016_j_annepidem_2021_07_001
S1047279721002052
Genre Journal Article
GroupedDBID ---
--K
--M
.1-
.FO
.~1
0R~
1B1
1P~
1~.
1~5
23M
4.4
457
4CK
4G.
53G
5GY
5RE
5VS
7-5
71M
8P~
9JM
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATTM
AAWTL
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABJNI
ABMAC
ABMZM
ABWVN
ABXDB
ACDAQ
ACGFS
ACIEU
ACIUM
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
AEBSH
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGQPQ
AGUBO
AGYEJ
AHHHB
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CS3
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HEH
HMK
HMO
HVGLF
HZ~
IHE
J1W
KOM
M41
MO0
N9A
O-L
O9-
OAUVE
OD~
OO0
OZT
P-8
P-9
P2P
PC.
Q38
R2-
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SEW
SPCBC
SSH
SSZ
T5K
UAP
WH7
XPP
Z5R
~G-
AACTN
AAIAV
ABLVK
ABYKQ
AFCTW
AFKWA
AJBFU
AJOXV
AMFUW
EFLBG
LCYCR
RIG
AAYXX
AGRNS
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c427t-39acd4b284db0f8feb70f0e327299b2873168429d25e98e43c6b6272a0784aa63
IEDL.DBID .~1
ISSN 1047-2797
1873-2585
IngestDate Fri Jul 11 03:13:06 EDT 2025
Mon Jul 21 05:49:56 EDT 2025
Thu Apr 24 22:53:10 EDT 2025
Tue Jul 01 03:11:40 EDT 2025
Fri Feb 23 02:43:40 EST 2024
Tue Aug 26 20:15:00 EDT 2025
IsPeerReviewed true
IsScholarly true
Keywords Clinical trials
Inverse probability weighting
Causalinference
Intention to treat
Marginal structural models
Language English
License Copyright © 2021 Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c427t-39acd4b284db0f8feb70f0e327299b2873168429d25e98e43c6b6272a0784aa63
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 34289408
PQID 2554354213
PQPubID 23479
PageCount 7
ParticipantIDs proquest_miscellaneous_2554354213
pubmed_primary_34289408
crossref_citationtrail_10_1016_j_annepidem_2021_07_001
crossref_primary_10_1016_j_annepidem_2021_07_001
elsevier_sciencedirect_doi_10_1016_j_annepidem_2021_07_001
elsevier_clinicalkey_doi_10_1016_j_annepidem_2021_07_001
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate November 2021
2021-11-00
20211101
PublicationDateYYYYMMDD 2021-11-01
PublicationDate_xml – month: 11
  year: 2021
  text: November 2021
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Annals of epidemiology
PublicationTitleAlternate Ann Epidemiol
PublicationYear 2021
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Faries, Kadziola (bib0019) 2010
Curtis, Hammill, Eisenstein, Kramer, Anstrom (bib0016) 2007; 45
Sumino, Holbrook, Wise, Rogers (bib0014) 2012; 1
Robins, Hernan (bib0005) 2009
Hernán, Brumback, Robins (bib0007) 2002; 21
Rossouw, Anderson, Prentice, LaCroix, Kooperberg, Stefanick (bib0029) 2002; 288
Toh, Hernandez-Diaz, Logan, Robins, Hernan (bib0028) 2010; 21
Bodnar, Davidian, Siega-Riz, Tsiatis (bib0006) 2004; 159
Rochon, Bhapkar, Pieper, Kraus (bib0012) 2016; 4
Hernán, Robins (bib0018) 2018
Dobson (bib0023) 2002
Zhang, Tsiatis, Davidian, Pieper, Mahaffey (bib0025) 2011; 12
The American Lung Association Asthma Clinical Research (bib0013) 2007; 175
Hernán, Hernández-Díaz (bib0001) 2012; 9
VanderWeele, Hawkley, Thisted, Cacioppo (bib0009) 2011; 79
Twisk (bib0021) 2013
Tepper, Wise, Covar, Irvin, Kercsmar, Kraft (bib0015) 2012; 129
.
Fox (bib0022) 2008
Crowson C.S., Schenck L.A., Green A.B., Atkinson E.J., Therneau T.M. The basics of propensity scoring and marginal structural models. Mayo Clinic Technical Report #84, August 1, 2013.
Robins, Hernán, Brumback (bib0003) 2000; 11
Hernán, Hernández-Díaz, Robins (bib0004) 2013; 159
(bib0024) 2018
Thoemmes, Ong (bib0020) 2016; 4
Sheiner (bib0002) 2002; 54
Toh, Hernán (bib0010) 2008; 4
Cook, Cole, Hennekens (bib0027) 2002; 155
Shortreed, Forbes (bib0008) 2010; 29
Cole, Hernán (bib0011) 2008; 168
Cain, Cole (bib0026) 2009; 28
The American Lung Association Asthma Clinical Research (10.1016/j.annepidem.2021.07.001_bib0013) 2007; 175
Toh (10.1016/j.annepidem.2021.07.001_bib0010) 2008; 4
Cook (10.1016/j.annepidem.2021.07.001_bib0027) 2002; 155
Shortreed (10.1016/j.annepidem.2021.07.001_bib0008) 2010; 29
VanderWeele (10.1016/j.annepidem.2021.07.001_bib0009) 2011; 79
Twisk (10.1016/j.annepidem.2021.07.001_bib0021) 2013
Hernán (10.1016/j.annepidem.2021.07.001_bib0004) 2013; 159
Hernán (10.1016/j.annepidem.2021.07.001_bib0007) 2002; 21
(10.1016/j.annepidem.2021.07.001_bib0024) 2018
Zhang (10.1016/j.annepidem.2021.07.001_bib0025) 2011; 12
10.1016/j.annepidem.2021.07.001_bib0017
Cain (10.1016/j.annepidem.2021.07.001_bib0026) 2009; 28
Faries (10.1016/j.annepidem.2021.07.001_bib0019) 2010
Thoemmes (10.1016/j.annepidem.2021.07.001_bib0020) 2016; 4
Rochon (10.1016/j.annepidem.2021.07.001_bib0012) 2016; 4
Sumino (10.1016/j.annepidem.2021.07.001_bib0014) 2012; 1
Fox (10.1016/j.annepidem.2021.07.001_bib0022) 2008
Dobson (10.1016/j.annepidem.2021.07.001_bib0023) 2002
Hernán (10.1016/j.annepidem.2021.07.001_bib0018) 2018
Cole (10.1016/j.annepidem.2021.07.001_bib0011) 2008; 168
Tepper (10.1016/j.annepidem.2021.07.001_bib0015) 2012; 129
Hernán (10.1016/j.annepidem.2021.07.001_bib0001) 2012; 9
Toh (10.1016/j.annepidem.2021.07.001_bib0028) 2010; 21
Robins (10.1016/j.annepidem.2021.07.001_bib0003) 2000; 11
Curtis (10.1016/j.annepidem.2021.07.001_bib0016) 2007; 45
Robins (10.1016/j.annepidem.2021.07.001_bib0005) 2009
Rossouw (10.1016/j.annepidem.2021.07.001_bib0029) 2002; 288
Sheiner (10.1016/j.annepidem.2021.07.001_bib0002) 2002; 54
Bodnar (10.1016/j.annepidem.2021.07.001_bib0006) 2004; 159
References_xml – volume: 175
  start-page: 235
  year: 2007
  end-page: 242
  ident: bib0013
  article-title: Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma
  publication-title: Am J Respir Crit Care Med
– year: 2018
  ident: bib0018
  article-title: . chapman & hall/crc, forthcoming
  publication-title: Causal Inference
– reference: Crowson C.S., Schenck L.A., Green A.B., Atkinson E.J., Therneau T.M. The basics of propensity scoring and marginal structural models. Mayo Clinic Technical Report #84, August 1, 2013.
– year: 2008
  ident: bib0022
  article-title: . second edi
  publication-title: Applied regression analysis and generalized linear models
– year: 2018
  ident: bib0024
  article-title: SAS 9.4
  publication-title: Copyright ©
– volume: 12
  start-page: 258
  year: 2011
  end-page: 269
  ident: bib0025
  article-title: Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial
  publication-title: Biostatistics
– volume: 9
  start-page: 48
  year: 2012
  end-page: 55
  ident: bib0001
  article-title: Beyond the intention-to-treat in comparative effectiveness research
  publication-title: Clin Trials
– volume: 21
  start-page: 528
  year: 2010
  end-page: 539
  ident: bib0028
  article-title: Estimating absolute risks in the presence of nonadherence: an application to a follow-up study with baseline randomization
  publication-title: Epidemiology
– volume: 79
  start-page: 225
  year: 2011
  end-page: 235
  ident: bib0009
  article-title: A marginal structural model analysis for loneliness: implications for intervention trials and clinical practice
  publication-title: J Consult Clin Psychol
– volume: 29
  start-page: 431
  year: 2010
  end-page: 433
  ident: bib0008
  article-title: Missing data in the exposure of interest and marginal structural models: a simulation study based on the framingham heart study
  publication-title: Stat Med
– volume: 4
  start-page: 40
  year: 2016
  end-page: 59
  ident: bib0020
  article-title: A primer on inverse probability of treatment weighting and marginal structural models
  publication-title: Emerging Adulthood
– year: 2013
  ident: bib0021
  article-title: Applied longitudinal data analysis for epidemiology: a practical guide
– volume: 11
  start-page: 550
  year: 2000
  end-page: 560
  ident: bib0003
  article-title: Marginal structural models and causal inference in epidemiology
  publication-title: Epidemiology
– volume: 21
  start-page: 1689
  year: 2002
  end-page: 1709
  ident: bib0007
  article-title: Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures
  publication-title: Stat Med
– volume: 168
  start-page: 656
  year: 2008
  end-page: 664
  ident: bib0011
  article-title: Constructing inverse probability weights for marginal structural models
  publication-title: Am J Epidemiol
– volume: 129
  start-page: S65
  year: 2012
  end-page: S87
  ident: bib0015
  article-title: Asthma outcomes: pulmonary physiology
  publication-title: J Allergy Clin Immunol
– start-page: 553
  year: 2009
  end-page: 599
  ident: bib0005
  article-title: Estimation of the causal effects of time-varying exposures
  publication-title: Longitudinal data analysis
– volume: 4
  start-page: 222
  year: 2016
  end-page: 228
  ident: bib0012
  article-title: Application of the marginal structural model to account for suboptimal adherence in a randomized controlled trial
  publication-title: Contemp Clin Trials Commun
– volume: 159
  start-page: 926
  year: 2004
  end-page: 934
  ident: bib0006
  article-title: Marginal structural models for analyzing causal effects of time-dependent treatments: an application in perinatal epidemiology
  publication-title: Am J Epidemiol
– reference: .
– volume: 1
  start-page: 251
  year: 2012
  end-page: 258
  ident: bib0014
  article-title: Asthma clinical trials of American lung association/asthma clinical research centers (ALA-ACRC): what have we learned in 12 years?
  publication-title: Curr Respir Care Rep
– volume: 45
  start-page: S103
  year: 2007
  end-page: S107
  ident: bib0016
  article-title: Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases
  publication-title: Med Care
– start-page: 211
  year: 2010
  end-page: 228
  ident: bib0019
  article-title: Analysis of longitudinal observational data using marginal structural models
  publication-title: Analysis of Observational Health Care Data Using SAS®
– year: 2002
  ident: bib0023
  article-title: An introduction to generalized linear models
– volume: 54
  start-page: 203
  year: 2002
  end-page: 211
  ident: bib0002
  article-title: Is intent-to-treat analysis always (ever) enough?
  publication-title: Br J Clin Pharmacol
– volume: 4
  start-page: Article 22
  year: 2008
  ident: bib0010
  article-title: Causal inference from longitudinal studies with baseline randomization
  publication-title: Int J Biostat
– volume: 28
  start-page: 1725
  year: 2009
  end-page: 1738
  ident: bib0026
  article-title: Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of randomized highly active antiretroviral therapy on incident AIDS or death
  publication-title: Stat Med
– volume: 159
  start-page: 560
  year: 2013
  end-page: 562
  ident: bib0004
  article-title: Randomized trials analyzed as observational studies
  publication-title: Ann Intern Med
– volume: 155
  start-page: 1045
  year: 2002
  end-page: 1053
  ident: bib0027
  article-title: Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians’ Health Study
  publication-title: Am J Epidemiol
– volume: 288
  start-page: 321
  year: 2002
  end-page: 333
  ident: bib0029
  article-title: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial
  publication-title: JAMA
– year: 2002
  ident: 10.1016/j.annepidem.2021.07.001_bib0023
– volume: 45
  start-page: S103
  issue: 10 Supl 2
  year: 2007
  ident: 10.1016/j.annepidem.2021.07.001_bib0016
  article-title: Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases
  publication-title: Med Care
  doi: 10.1097/MLR.0b013e31806518ac
– volume: 29
  start-page: 431
  issue: 4
  year: 2010
  ident: 10.1016/j.annepidem.2021.07.001_bib0008
  article-title: Missing data in the exposure of interest and marginal structural models: a simulation study based on the framingham heart study
  publication-title: Stat Med
  doi: 10.1002/sim.3801
– year: 2008
  ident: 10.1016/j.annepidem.2021.07.001_bib0022
  article-title: Applied regression analysis and generalized linear models. second edi
– start-page: 211
  year: 2010
  ident: 10.1016/j.annepidem.2021.07.001_bib0019
  article-title: Analysis of longitudinal observational data using marginal structural models
– volume: 4
  start-page: 222
  year: 2016
  ident: 10.1016/j.annepidem.2021.07.001_bib0012
  article-title: Application of the marginal structural model to account for suboptimal adherence in a randomized controlled trial
  publication-title: Contemp Clin Trials Commun
  doi: 10.1016/j.conctc.2016.10.005
– volume: 1
  start-page: 251
  issue: 4
  year: 2012
  ident: 10.1016/j.annepidem.2021.07.001_bib0014
  article-title: Asthma clinical trials of American lung association/asthma clinical research centers (ALA-ACRC): what have we learned in 12 years?
  publication-title: Curr Respir Care Rep
  doi: 10.1007/s13665-012-0024-y
– volume: 129
  start-page: S65
  issue: 3 Suppl
  year: 2012
  ident: 10.1016/j.annepidem.2021.07.001_bib0015
  article-title: Asthma outcomes: pulmonary physiology
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/j.jaci.2011.12.986
– year: 2018
  ident: 10.1016/j.annepidem.2021.07.001_bib0024
  article-title: SAS 9.4
  publication-title: Copyright ©
– volume: 175
  start-page: 235
  issue: 3
  year: 2007
  ident: 10.1016/j.annepidem.2021.07.001_bib0013
  article-title: Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.200603-416OC
– start-page: 553
  year: 2009
  ident: 10.1016/j.annepidem.2021.07.001_bib0005
  article-title: Estimation of the causal effects of time-varying exposures
– volume: 288
  start-page: 321
  year: 2002
  ident: 10.1016/j.annepidem.2021.07.001_bib0029
  article-title: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial
  publication-title: JAMA
  doi: 10.1001/jama.288.3.321
– volume: 28
  start-page: 1725
  issue: 12
  year: 2009
  ident: 10.1016/j.annepidem.2021.07.001_bib0026
  article-title: Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of randomized highly active antiretroviral therapy on incident AIDS or death
  publication-title: Stat Med
  doi: 10.1002/sim.3585
– volume: 4
  start-page: 40
  issue: 1
  year: 2016
  ident: 10.1016/j.annepidem.2021.07.001_bib0020
  article-title: A primer on inverse probability of treatment weighting and marginal structural models
  publication-title: Emerging Adulthood
  doi: 10.1177/2167696815621645
– volume: 4
  start-page: Article 22
  issue: 1
  year: 2008
  ident: 10.1016/j.annepidem.2021.07.001_bib0010
  article-title: Causal inference from longitudinal studies with baseline randomization
  publication-title: Int J Biostat
  doi: 10.2202/1557-4679.1117
– volume: 9
  start-page: 48
  issue: 1
  year: 2012
  ident: 10.1016/j.annepidem.2021.07.001_bib0001
  article-title: Beyond the intention-to-treat in comparative effectiveness research
  publication-title: Clin Trials
  doi: 10.1177/1740774511420743
– volume: 168
  start-page: 656
  issue: 6
  year: 2008
  ident: 10.1016/j.annepidem.2021.07.001_bib0011
  article-title: Constructing inverse probability weights for marginal structural models
  publication-title: Am J Epidemiol
  doi: 10.1093/aje/kwn164
– volume: 159
  start-page: 926
  issue: 10
  year: 2004
  ident: 10.1016/j.annepidem.2021.07.001_bib0006
  article-title: Marginal structural models for analyzing causal effects of time-dependent treatments: an application in perinatal epidemiology
  publication-title: Am J Epidemiol
  doi: 10.1093/aje/kwh131
– volume: 79
  start-page: 225
  issue: 2
  year: 2011
  ident: 10.1016/j.annepidem.2021.07.001_bib0009
  article-title: A marginal structural model analysis for loneliness: implications for intervention trials and clinical practice
  publication-title: J Consult Clin Psychol
  doi: 10.1037/a0022610
– volume: 21
  start-page: 1689
  issue: 12
  year: 2002
  ident: 10.1016/j.annepidem.2021.07.001_bib0007
  article-title: Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures
  publication-title: Stat Med
  doi: 10.1002/sim.1144
– volume: 21
  start-page: 528
  year: 2010
  ident: 10.1016/j.annepidem.2021.07.001_bib0028
  article-title: Estimating absolute risks in the presence of nonadherence: an application to a follow-up study with baseline randomization
  publication-title: Epidemiology
  doi: 10.1097/EDE.0b013e3181df1b69
– volume: 159
  start-page: 560
  issue: 8
  year: 2013
  ident: 10.1016/j.annepidem.2021.07.001_bib0004
  article-title: Randomized trials analyzed as observational studies
  publication-title: Ann Intern Med
– volume: 54
  start-page: 203
  issue: 2
  year: 2002
  ident: 10.1016/j.annepidem.2021.07.001_bib0002
  article-title: Is intent-to-treat analysis always (ever) enough?
  publication-title: Br J Clin Pharmacol
  doi: 10.1046/j.1365-2125.2002.01628.x
– year: 2013
  ident: 10.1016/j.annepidem.2021.07.001_bib0021
– volume: 12
  start-page: 258
  issue: 2
  year: 2011
  ident: 10.1016/j.annepidem.2021.07.001_bib0025
  article-title: Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial
  publication-title: Biostatistics
  doi: 10.1093/biostatistics/kxq054
– year: 2018
  ident: 10.1016/j.annepidem.2021.07.001_bib0018
  article-title: Causal inference. chapman & hall/crc, forthcoming
– volume: 11
  start-page: 550
  issue: 5
  year: 2000
  ident: 10.1016/j.annepidem.2021.07.001_bib0003
  article-title: Marginal structural models and causal inference in epidemiology
  publication-title: Epidemiology
  doi: 10.1097/00001648-200009000-00011
– ident: 10.1016/j.annepidem.2021.07.001_bib0017
– volume: 155
  start-page: 1045
  issue: 11
  year: 2002
  ident: 10.1016/j.annepidem.2021.07.001_bib0027
  article-title: Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians’ Health Study
  publication-title: Am J Epidemiol
  doi: 10.1093/aje/155.11.1045
SSID ssj0007872
Score 2.3497941
Snippet •Unlike the Intention-to-Treat approach, Marginal Structural Models can account for the effects of time-varying treatments in the presence of censoring and...
In the presence of non-adherence and lost to follow up, results of an Intention to Treat (ITT) analysis may be biased as it is measuring the effect of...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 22
SubjectTerms Causalinference
Clinical trials
Humans
Intention to treat
Intention to Treat Analysis
Inverse probability weighting
Lost to Follow-Up
Marginal structural models
Models, Structural
Patient Compliance
Randomized Controlled Trials as Topic
Title Using marginal structural models to analyze randomized clinical trials with non-adherence and lost to follow up
URI https://www.clinicalkey.com/#!/content/1-s2.0-S1047279721002052
https://dx.doi.org/10.1016/j.annepidem.2021.07.001
https://www.ncbi.nlm.nih.gov/pubmed/34289408
https://www.proquest.com/docview/2554354213
Volume 63
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS8MwEA9jgggiOr_mFxF8rWvT9Mu3MRxT2V50sLeQLClOtnW4DWEP_u1ekrYyUCb42LTXtMnlPpK73yF0AyY2TxMSOokrhUMjIZxYKVh4XhoTTocB9XVycrcXdvr0cRAMKqhV5MLosMpc9luZbqR13tLIR7MxG40azxpkgEQafUbbPIGWw5RGmstvP7_DPIAhSYlIAE-vxXhxkGWmECs4isQzKJ55dZgfNNRvFqjRRO19tJebkLhpv_IAVdS0hra7-SF5De3arThsM4wOUWbCAvCEv5sSWNhCxmq4DWzq4MzxIsNcg5OsFAbVJbPJaKUkLpImsansMcd6yxZPs6nD5atNEgQqicfZfKHfkAJHZR94OTtC_fb9S6vj5HUWnCEl0cLxEz6UVICiksJN41SJyE1d5RMwvBNoNsWtQG9JEqgkVjB7oQjhJofBpZyH_jGqQu_qFGEVqSgWHKh4DKZJwpWk0pOJCMAt9JRXR2ExtmyYg5DrWhhjVkSbvbFyUpieFObqA3IgdEvCmcXh2EwSF5PHihEDwchAV2wmvStJ17jxb8TXBacwWKv6AIZPVbacM3DfwDqlxPPr6MSyUPkzPviBCXXjs_90fY529JXNlbxAVeAndQlG00JcmVVxhbaaD0-d3hc2tBfh
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dT9RAEJ8gJmpCiKIo-LUm-liv3W6_THgwKDmE40VIeFt3b6fhCFwv9giBB_4p_0FnP1pCosHE8NrNtNvZ2d_M7M4HwHsysVVd8TyqYqMjUWgdlYi08ZK65EqMM5Ha5OTRXj48EN8Os8MF-NXlwtiwyoD9HtMdWocng8DNwWwyGXy3RQZ4YavPWJsn4yGycgcvzslvaze2v9Aif-B86-v-5jAKrQWiseDFPEorNTZCEzYbHddljbqI6xhTTrZmRY9dPyeCasMzrEqkCec6p0FFGlUolaf03ntwXxBc2LYJH6-u40poB_C-BAJN70ZQmSLwdJ1fyTPliSsbGtrR_EEl_s3kdapv6zEsB5uVffZseQILOF2BB6NwK78CS_7sj_mUpqfQuDgEdqp-up5bzNeotfU9mGu807J5w5SthnKJjHSlaU4nl2hYl6XJXCuRltkzYjZtppEyRz4rkagMO2nauX1DTSLcnLOz2TM4uBPur8IifR1fAMMCi1IrolIl2UKVQiNMYiqdkR-aYLIGecdbOQ5Vz23zjRPZhbcdy35RpF0UGdsbeSKMe8KZL_xxO0nZLZ7sOEZILEk53U76qSe9If7_RvyukxRJ4GBvfNQUm7NWkr9I5rDgSboGz70I9T-TkuNZibhc_59Pv4WHw_3Rrtzd3tt5CY_siE_UfAWLJFv4miy2uX7jdgiDH3e9JX8D8eJSRw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Using+marginal+structural+models+to+analyze+randomized+clinical+trials+with+non-adherence+and+lost+to+follow+up&rft.jtitle=Annals+of+epidemiology&rft.au=Lancet%2C+Elizabeth+A.&rft.au=Borrell%2C+Luisa+N.&rft.au=Holbrook%2C+Janet&rft.au=Morabia%2C+Alfredo&rft.date=2021-11-01&rft.pub=Elsevier+Inc&rft.issn=1047-2797&rft.eissn=1873-2585&rft.volume=63&rft.spage=22&rft.epage=28&rft_id=info:doi/10.1016%2Fj.annepidem.2021.07.001&rft.externalDocID=S1047279721002052
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1047-2797&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1047-2797&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1047-2797&client=summon